Join for an exclusive event exploring the recent approval of ROMVIMZA™ (vimseltinib), a new treatment for adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity.
